Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01419665




Registration number
NCT01419665
Ethics application status
Date submitted
17/08/2011
Date registered
18/08/2011
Date last updated
14/05/2021

Titles & IDs
Public title
GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)
Scientific title
A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 vs. MabThera® in Patients With Previously Untreated, Advanced Stage Follicular Lymphoma
Secondary ID [1] 0 0
2010-019522-13
Secondary ID [2] 0 0
GP13-301
Universal Trial Number (UTN)
Trial acronym
ASSIST_FL
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Follicular Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - GP2013
Treatment: Other - rituximab

Experimental: GP2013 - Type: Biological/Vaccine

Active comparator: rituximab - Type: Biological/Vaccine


Treatment: Other: GP2013
Type: Biological/Vaccine

Treatment: Other: rituximab
Type: Biological/Vaccine
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Response Rate (ORR)
Timepoint [1] 0 0
24 weeks
Secondary outcome [1] 0 0
To Evaluate the Complete Response (CR) Rate During the Combination Treatment Period
Timepoint [1] 0 0
24 weeks
Secondary outcome [2] 0 0
To Evaluate the Partial Response (PR) Rate During the Combination Treatment Period
Timepoint [2] 0 0
24 weeks
Secondary outcome [3] 0 0
To Evaluate the Progression Free Survival (PFS) With up to 3 Years of Follow-up Post Randomization
Timepoint [3] 0 0
3 years
Secondary outcome [4] 0 0
To Evaluate the Overall Survival (OS) With up to 3 Years of Follow-up Post Randomization, as Assessed by the Number of Deaths
Timepoint [4] 0 0
3 years
Secondary outcome [5] 0 0
To Evaluate the Incidence of Immunogenicity (ADA Formation) Against GP2013 and MabThera (Rituximab)
Timepoint [5] 0 0
24 weeks, 3 years
Secondary outcome [6] 0 0
To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Max)
Timepoint [6] 0 0
day 63
Secondary outcome [7] 0 0
To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Trough)
Timepoint [7] 0 0
day 63
Secondary outcome [8] 0 0
To Evaluate a PD Marker (Peripheral CD19+ B-cell Counts) Following the Treatment With GP2013 + Chemotherapy Amd MabThera- Chemotherapy
Timepoint [8] 0 0
21 days

Eligibility
Key inclusion criteria
* Patient with previously untreated advanced stage, CD20-positive FL
* Patient with ECOG performance status 0, 1 or 2.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patient with Grade 3b (aggressive) FL or any histology other than FL grade 1, 2 or 3a
* Patient who has previously received any prior therapy for lymphoma
* Patient with evidence of any uncontrolled, active infection (viral, bacterial or fungal).
* Patient with any malignancy within 5 years prior to date of randomization, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer.

Other protocol-defined inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
22/01/2018
Sample size
Target
Accrual to date
Final
629
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Investigative site - Adelaide
Recruitment hospital [2] 0 0
Investigative site - Ballarat
Recruitment hospital [3] 0 0
Investigative site - Epping
Recruitment hospital [4] 0 0
Investigative site - Footscray
Recruitment hospital [5] 0 0
Investigative site - Wodonga
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Ballarat
Recruitment postcode(s) [3] 0 0
- Epping
Recruitment postcode(s) [4] 0 0
- Footscray
Recruitment postcode(s) [5] 0 0
- Wodonga
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
La Plata
Country [2] 0 0
Argentina
State/province [2] 0 0
Rosario
Country [3] 0 0
Argentina
State/province [3] 0 0
San Miguel de Tucuman
Country [4] 0 0
Austria
State/province [4] 0 0
Graz
Country [5] 0 0
Austria
State/province [5] 0 0
Wien
Country [6] 0 0
Brazil
State/province [6] 0 0
Barretos
Country [7] 0 0
Brazil
State/province [7] 0 0
Botucatu
Country [8] 0 0
Brazil
State/province [8] 0 0
Campinas
Country [9] 0 0
Brazil
State/province [9] 0 0
Curitiba
Country [10] 0 0
Brazil
State/province [10] 0 0
Florianopolis
Country [11] 0 0
Brazil
State/province [11] 0 0
Fortaleza
Country [12] 0 0
Brazil
State/province [12] 0 0
Goiania
Country [13] 0 0
Brazil
State/province [13] 0 0
Jau
Country [14] 0 0
Brazil
State/province [14] 0 0
Passo Fundo
Country [15] 0 0
Brazil
State/province [15] 0 0
Porto Alegre
Country [16] 0 0
Brazil
State/province [16] 0 0
Rio de Janeiro
Country [17] 0 0
Brazil
State/province [17] 0 0
Santo Andre
Country [18] 0 0
Brazil
State/province [18] 0 0
Sao Paulo
Country [19] 0 0
Brazil
State/province [19] 0 0
Sorocaba
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Pleven
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Plovdiv
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Ruse
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Sofia
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Varna
Country [25] 0 0
Colombia
State/province [25] 0 0
Medellin
Country [26] 0 0
Colombia
State/province [26] 0 0
Monteria
Country [27] 0 0
France
State/province [27] 0 0
Colmar
Country [28] 0 0
France
State/province [28] 0 0
Nimes
Country [29] 0 0
France
State/province [29] 0 0
Strasbourg
Country [30] 0 0
Germany
State/province [30] 0 0
Bad Saarow
Country [31] 0 0
Germany
State/province [31] 0 0
Koblenz
Country [32] 0 0
Greece
State/province [32] 0 0
Athens
Country [33] 0 0
Greece
State/province [33] 0 0
Ioannina
Country [34] 0 0
Greece
State/province [34] 0 0
Larissa
Country [35] 0 0
Greece
State/province [35] 0 0
Patras
Country [36] 0 0
Hungary
State/province [36] 0 0
Györ
Country [37] 0 0
Hungary
State/province [37] 0 0
Kaposvar
Country [38] 0 0
India
State/province [38] 0 0
Ahmedabad
Country [39] 0 0
India
State/province [39] 0 0
Amritsar
Country [40] 0 0
India
State/province [40] 0 0
Aurangabad
Country [41] 0 0
India
State/province [41] 0 0
Bangalore
Country [42] 0 0
India
State/province [42] 0 0
Chennai
Country [43] 0 0
India
State/province [43] 0 0
Hyderabad
Country [44] 0 0
India
State/province [44] 0 0
Kolkata
Country [45] 0 0
India
State/province [45] 0 0
Madurai
Country [46] 0 0
India
State/province [46] 0 0
Mumbai
Country [47] 0 0
India
State/province [47] 0 0
Nashik
Country [48] 0 0
India
State/province [48] 0 0
New Delhi
Country [49] 0 0
India
State/province [49] 0 0
Pune
Country [50] 0 0
India
State/province [50] 0 0
Surat
Country [51] 0 0
India
State/province [51] 0 0
Trivandrum
Country [52] 0 0
India
State/province [52] 0 0
Vellore
Country [53] 0 0
Ireland
State/province [53] 0 0
Dublin
Country [54] 0 0
Ireland
State/province [54] 0 0
Limerick
Country [55] 0 0
Ireland
State/province [55] 0 0
Waterford
Country [56] 0 0
Israel
State/province [56] 0 0
Ashkelon
Country [57] 0 0
Israel
State/province [57] 0 0
Nahariya
Country [58] 0 0
Italy
State/province [58] 0 0
Bari
Country [59] 0 0
Italy
State/province [59] 0 0
Firenze
Country [60] 0 0
Italy
State/province [60] 0 0
Meldola
Country [61] 0 0
Italy
State/province [61] 0 0
Milano
Country [62] 0 0
Italy
State/province [62] 0 0
Palermo
Country [63] 0 0
Italy
State/province [63] 0 0
Pavia
Country [64] 0 0
Italy
State/province [64] 0 0
Pescara
Country [65] 0 0
Italy
State/province [65] 0 0
Piacenza
Country [66] 0 0
Italy
State/province [66] 0 0
Ravenna
Country [67] 0 0
Italy
State/province [67] 0 0
Reggio Calabria
Country [68] 0 0
Italy
State/province [68] 0 0
Varese
Country [69] 0 0
Japan
State/province [69] 0 0
Aomori
Country [70] 0 0
Japan
State/province [70] 0 0
Fukuoka
Country [71] 0 0
Japan
State/province [71] 0 0
Gifu
Country [72] 0 0
Japan
State/province [72] 0 0
Kagoshima
Country [73] 0 0
Japan
State/province [73] 0 0
Kitakyushu
Country [74] 0 0
Japan
State/province [74] 0 0
Kobe
Country [75] 0 0
Japan
State/province [75] 0 0
Komaki
Country [76] 0 0
Japan
State/province [76] 0 0
Matsuyama
Country [77] 0 0
Japan
State/province [77] 0 0
Ogaki
Country [78] 0 0
Japan
State/province [78] 0 0
Okayama
Country [79] 0 0
Japan
State/province [79] 0 0
Omura
Country [80] 0 0
Japan
State/province [80] 0 0
Saga
Country [81] 0 0
Japan
State/province [81] 0 0
Tachikawa
Country [82] 0 0
Japan
State/province [82] 0 0
Otake
Country [83] 0 0
Malaysia
State/province [83] 0 0
Alor Setar
Country [84] 0 0
Malaysia
State/province [84] 0 0
Ampang
Country [85] 0 0
Malaysia
State/province [85] 0 0
George Town
Country [86] 0 0
Malaysia
State/province [86] 0 0
Ipoh
Country [87] 0 0
Malaysia
State/province [87] 0 0
Johor Bahru
Country [88] 0 0
Malaysia
State/province [88] 0 0
Klang
Country [89] 0 0
Malaysia
State/province [89] 0 0
Kuala Lumpur
Country [90] 0 0
Malaysia
State/province [90] 0 0
Kuching
Country [91] 0 0
Malaysia
State/province [91] 0 0
Melaka
Country [92] 0 0
Malaysia
State/province [92] 0 0
Pulau Pinang
Country [93] 0 0
Malaysia
State/province [93] 0 0
Subang Jaya
Country [94] 0 0
Netherlands
State/province [94] 0 0
Amsterdam
Country [95] 0 0
Netherlands
State/province [95] 0 0
Delft
Country [96] 0 0
Netherlands
State/province [96] 0 0
Gouda
Country [97] 0 0
Netherlands
State/province [97] 0 0
Heerlen
Country [98] 0 0
Netherlands
State/province [98] 0 0
Rotterdam
Country [99] 0 0
Netherlands
State/province [99] 0 0
Schiedam
Country [100] 0 0
Netherlands
State/province [100] 0 0
Sittard
Country [101] 0 0
Netherlands
State/province [101] 0 0
Zwolle
Country [102] 0 0
Peru
State/province [102] 0 0
Lima
Country [103] 0 0
Poland
State/province [103] 0 0
Brzozow
Country [104] 0 0
Poland
State/province [104] 0 0
Bydgoszcz
Country [105] 0 0
Poland
State/province [105] 0 0
Chorzow
Country [106] 0 0
Poland
State/province [106] 0 0
Krakow
Country [107] 0 0
Poland
State/province [107] 0 0
Lublin
Country [108] 0 0
Poland
State/province [108] 0 0
Warszawa
Country [109] 0 0
Portugal
State/province [109] 0 0
Braga
Country [110] 0 0
Portugal
State/province [110] 0 0
Coimbra
Country [111] 0 0
Portugal
State/province [111] 0 0
Lisboa
Country [112] 0 0
Portugal
State/province [112] 0 0
Porto
Country [113] 0 0
Romania
State/province [113] 0 0
Brasov
Country [114] 0 0
Romania
State/province [114] 0 0
Bucharest
Country [115] 0 0
Romania
State/province [115] 0 0
Cluj-Napoca
Country [116] 0 0
Romania
State/province [116] 0 0
Iasi
Country [117] 0 0
Romania
State/province [117] 0 0
Timisoara
Country [118] 0 0
Russian Federation
State/province [118] 0 0
Arkhangelsk
Country [119] 0 0
Russian Federation
State/province [119] 0 0
Chelyabinsk
Country [120] 0 0
Russian Federation
State/province [120] 0 0
Krasnodar
Country [121] 0 0
Russian Federation
State/province [121] 0 0
Kursk
Country [122] 0 0
Russian Federation
State/province [122] 0 0
Moscow
Country [123] 0 0
Russian Federation
State/province [123] 0 0
Nizhniy Novgorod
Country [124] 0 0
Russian Federation
State/province [124] 0 0
Rostov-on -Don
Country [125] 0 0
Russian Federation
State/province [125] 0 0
St. Petersburg
Country [126] 0 0
South Africa
State/province [126] 0 0
Cape Town
Country [127] 0 0
South Africa
State/province [127] 0 0
George
Country [128] 0 0
South Africa
State/province [128] 0 0
Johannesburg
Country [129] 0 0
South Africa
State/province [129] 0 0
Port Elizabeth
Country [130] 0 0
South Africa
State/province [130] 0 0
Pretoria
Country [131] 0 0
Spain
State/province [131] 0 0
Barcelona
Country [132] 0 0
Spain
State/province [132] 0 0
Madrid
Country [133] 0 0
Spain
State/province [133] 0 0
Oviedo
Country [134] 0 0
Spain
State/province [134] 0 0
San Sebastian
Country [135] 0 0
Spain
State/province [135] 0 0
Sevilla
Country [136] 0 0
Spain
State/province [136] 0 0
Zaragoza
Country [137] 0 0
Ukraine
State/province [137] 0 0
Cherkasy
Country [138] 0 0
Ukraine
State/province [138] 0 0
Dnipropetrovsk
Country [139] 0 0
Ukraine
State/province [139] 0 0
Donetsk
Country [140] 0 0
Ukraine
State/province [140] 0 0
Ivano-Frankivsk
Country [141] 0 0
Ukraine
State/province [141] 0 0
Kharkiv
Country [142] 0 0
Ukraine
State/province [142] 0 0
Kyiv
Country [143] 0 0
Ukraine
State/province [143] 0 0
Lviv
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Eastbourne
Country [145] 0 0
United Kingdom
State/province [145] 0 0
London
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Worthing

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Sandoz
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Novartis Pharmaceuticals
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to demonstrate comparability of the ORR in patients with previously untreated, advanced stage FL who receive GP2013-treatment to patients who receive MabThera-treatment.
Trial website
https://clinicaltrials.gov/study/NCT01419665
Trial related presentations / publications
Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, Castro N, Pereira J, Akria L, Alexeev S, Osmanov E, Zhu P, Alexandrova S, Zubel A, Harlin O, Amersdorffer J. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017 Aug;4(8):e350-e361. doi: 10.1016/S2352-3026(17)30106-0. Epub 2017 Jul 14.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01419665